Immune system therapy (ICT), a multinational biotech company specializing in developing monoclonal antibodies for hematological malignant neoplasms and autoimmune diseases. IST has found two new drug lasix drug generic targets, Kappa myeloma antigen (KMA) and lambda myeloma antigen (LMA), on the surface of human blood cancer and autoimmune cells. These tasks are very specific to abnormal B-cells were detected in blood cancers such as multiple myeloma (MM), lymphoma, leukemia and makrohlobulinemiya Valdenstrema.
In the CMA and LMA is not on healthy cells, treatment of IST should have few side effects. JV leading therapy, MDX-1097, is the first in its class, disease-modifying antibody therapy for treatment of malignant hematological diseases, appointed for the new B-cell surface antigen (KMA), characteristic of malignant cells. The leading indication for MDX-1097 is a kappa-type multiple myeloma, a deadly blood cancer, affecting more than 100,000 patients worldwide. MDX-1097 recently received FDA orphan drug designation for multiple myeloma in the FDA. These completed Phase I study and preliminary results from ongoing Phase II study in multiple myeloma show that the MDX-1097 is effective as monotherapy with excellent safety and tolerability in patients who received more prior lines of therapy. Based on current clinical profile and mechanism of action, key opinion leaders in the U.S. and EU of MDX-1097 at this stage of his development as a potentially important therapeutic tool for treating multiple myeloma and other blood cancer. Vision: To cure, improve survival and eliminate the suffering of people suffering from blood cancer and autoimmune diseases
No comments:
Post a Comment